Anti-properdin antibodies and uses thereof

Abstract

This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-properdin antibody. Specifically, the invention relates to methods of treating an AP-mediated pathology or AP-mediated condition in an individual by contacting the individual with an anti-properdin antibody.

1 .- 47 . (canceled) 
     
     
         48 . A composition comprising an antibody that binds to properdin and competes with the binding of (1) an antibody that comprises the CDRs: VH-CDR1: SEQ ID NO:3; VH-CDR2: SEQ ID NO:4; VH-CDR3: SEQ ID NO:5; VL-CDR1: SEQ ID NO:8; VL-CDR2: SEQ ID NO:9; and VL-CDR3: SEQ ID NO: 10, (2) an antibody that comprises the CDRs: VH-CDR1: SEQ ID NO:13; VH-CDR2: SEQ ID NO:14; VH-CDR3: SEQ ID NO:15; VL-CDR 1: SEQ ID NO:18; VL-CDR2: SEQ ID NO:19; and VL-CDR3: SEQ ID NO:20, (3) an antibody that comprises the CDRs: VH-CDR1: SEQ ID NO:23; VH-CDR2: SEQ ID NO:24; VH-CDR3: SEQ ID NO:25; VL-CDR 1: SEQ ID NO:28; VL-CDR2: SEQ ID NO:29; and VL-CDR3: SEQ ID NO:30, or (4) an antibody comprises the CDRs: VH-CDR1: SEQ ID NO:33; VH-CDR2: SEQ ID NO:34; VH-CDR3: SEQ ID NO:35; VL-CDR 1: SEQ ID NO:38; VL-CDR2: SEQ ID NO:39; and VL-CDR3: SEQ ID NO:40, to properdin. 
     
     
         49 . A composition comprising an antibody that binds to properdin and competes with the binding of the antibody designated mAB 19.1 to properdin. 
     
     
         50 . A composition comprising an antibody that binds to properdin and competes with the binding of the antibody designated mAB 25 to properdin. 
     
     
         51 . A composition comprising an antibody that binds to properdin and competes with the binding of the antibody designated mAB 22.1 to properdin. 
     
     
         52 . A composition comprising an antibody that binds to properdin and competes with the binding of the antibody designated mAB 30 to properdin. 
     
     
         53 .- 58 . (canceled)